Powered By
BIOCARTA Europe GmbH
Borsteler Chaussee 53, D-22453 Hamburg Germany
Tel +49-40-5257030 Fax +49-40-52570377
info.de@biocarta.com
Prostate Specific Acid
Phosphatase (PSAP)
Concentrated Monoclonal Antibody
Cat. #CM046A: 0.1 ml, Cat. #CM046B: 0.5 ml, Cat. #CM046C: 1.0 ml
Specificity and Comments:
Protein Block
Recognizes a protein of 52kDa, identified as the prostate specific acid
phosphatase (PSAP). Monoclonal PASE/4LJ is highly specific to
PSAP and shows no cross-reaction with other phosphatases. It does
not inhibit the enzymatic activity of PSAP. PASE/4LJ reacts with
non-neoplastic adult and fetal prostatic glands, primary and
metastatic prostatic carcinomas. PASE/4LJ is excellent for
immunohistochemical staining of formalin-fixed, paraffin-embedded
tissues. Unlike polyclonal antibody to PSAP, the monoclonal shows
no staining in granulocytes, osteoclasts, parietal cells of the stomach,
liver cells, renal cell or breast carcinomas.
Incubate for 5 minutes at room temperature (RT) with BIOCARE’S
BACKGROUNDERASER.
Species Reactivity:
Enzyme Labeled Streptavidin
Human, dog, rabbit, and rat; others not known.
Clone: PASE/4LJ.
Isotype: IgG1
Immunogen:
Purified prostatic acid phosphatase (PSAP) from human seminal
plasma.
Hybridoma:
Produced by fusion between Swiss A2G splenocytes and mouse
myeloma P3XAAg8.653 (NS1) cells.
Primary Antibody
Dilute 1:50-1:100. Incubate for 30-60 minutes at RT.
Biotinylated Secondary Antibody
Incubate for 10 minutes at RT. Use BIOCARE’S 4plus Detection
System.
Incubate for 10 minutes at RT with BIOCARE’S 4plus Detection
System.
Chromogen
Incubate
for
5-10
CHROMOGENCARE.
minutes.
Use
BIOCARE’S
Technical Note:
PSAP staining on over-fixed tissues is dramatically improved with
heat-retrieval methods.
Protocol Notes
Cellular Localization: Cytoplasmic.
The optimum antibody dilution and protocols for a specific
application can vary due to many factors. These include, but are not
limited to: fixation, incubation times, tissue section thickness and
detection kit used. The data sheet’s recommendations and protocols
are based on exclusive use of BIOCARE products. Due to the
superior sensitivity of these unique reagents, the recommended
incubation times and titers listed are not applicable to other detection
systems, as results may vary. Ultimately, it is the responsibility of
the investigator to determine optimal conditions.
Supplied As:
Limitations and Warranty
Tissue culture supernatant with preservative.
This antibody is available for research use only. Not approved for
use in humans or in clinical diagnosis. There are no warranties,
expressed or implied, which extend beyond this description.
BIOCARE is not liable for property damage, personal injury, or
economic loss caused by this product.
Known Applications: Immunohistochemistry (frozen and
formalin-fixed/paraffin-embedded).
Positive Control: Prostate or prostate carcinoma.
Storage and Stability:
Store vial at 4°C. Antibody is stable for 18 months.
Protocol Recommendations:
Endogenous Peroxidase Block
If using an HRP system, block for 5 minutes with BIOCARE’S
PEROXIDAZED 1.
For Research use only. Not for therapeutic or in vitro diagnostic use.
Revised 2/12/16
References:
1.
Ljung G, Norberg M, Holmberg L, Busch C, Nilsson S.
Characterization of residual tumor cells following radical
radiation
therapy
for
prostatic
adenocarcinoma;
immunohistochemical expression prostate-specific antigen,
- Page 1 -
2.
3.
4.
5.
6.
prostatic acid phosphatase, and cytokeratin 8.
Prostate,
May1;31(2):91-97, 1997.
Oberneder R, Riesenberg R, Kriegmair M, Bitzer U, Klammert
R, Schneede P, Hofstetter A, Riethmuller G, Pantel K.
immunocytochemical detection and phenotypic characterization
of micrometastatic tumour cells in bone marrow of patients with
prostate cancer. Urol Res, 22(1):3-8, 1994.
Epstein JI. PSA and PAP as immuno-histochemical markers in
prostate cancer. Urologic Clinics of North America, 1993
Nov, 20(4):757-70.
Sakai H; Yogi Y; Minami Y; Yushita Y; Kanetake H; Saito Y.
Prostate specific antigen and prostatic acid phosphatase
immunoreactivity as prognostic indicators of advanced prostatic
carcinoma. Journal of Urology, 1993, 149:1020-3.
Ersev A, Ersev D, Turkeri L, Ilker Y, Simsek F, Kullu S, Akdas
A. The relation of prostatic acid phosphatase and prostate
specific antigen with tumour grade in prostatic
adenocarcinoma:and immunohistochemical study. Prog Clin
Biol Res, 357:129-134, 1990.
Friedmann W, steffens J, Lobeck H. Blumcke S, Nagel R.
Immunohistochemical demonstration of tumor-associated
antigens in prostatic carcinomas of various histological
differentiations. Eur Urol, 11(1):52-56, 1985.
BIOCARE Products
Catalog #
Size
.
Product
Description
BE965H
BE965M
25ml
500ml
BACKGROUNDERASER
Blocking serum
HP504UR
HP504US
50ml
100ml
4plus HRP 500 Universal
Link and label for HRP detection systems
AC800P
DB801R
25ml
50ml
AEC250 Chromogen Pack
DAB500 Chromogen Pack
AEC – Liquid, two-component
DAB – Liquid, two-component
SFH1103A
SFH1103B
1 gross
10 gross
Kling-On HIER SLIDES
Super charged slides for tissues requiring heatinduced epitope retrieval methods (HIER)
For Research use only. Not for therapeutic or in vitro diagnostic use.
Revised 2/12/16
- Page 2 -